📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies. (2022)

First Author: Spencer AJ

Attributed to: G2P-UK; A National Virology Consortium to address phenotypic consequences of SARSCoV-2 genomic variation funded by COVID

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.ebiom.2022.103902

PubMed Identifier: 35228013

Publication URI: http://europepmc.org/abstract/MED/35228013

Type: Journal Article/Review

Volume: 77

Parent Publication: EBioMedicine

ISSN: 2352-3964